Type 2 diabetes patients with constipation show worse upper GI symptoms, longer disease duration, and higher rates of autonomic neuropathy, nephropathy, and hyperlipidemia versus non-constipated peers. They exhibit lower fasting C-peptide alongside elevated HbA1c, total cholesterol, and LDL-C, signaling metabolic disarray. Continuous glucose monitoring reveals lower time-in-range (TIR) and higher coefficient of variation (CV) strongly correlate with constipation risk, positioning these metrics as potential predictors via ROC analysis, with worse gastroparesis and quality-of-life scores confirming gut-brain axis disruption. Master glucose stability stop T2DM constipation before it starts!
To Read more Click Here ##Reference## Fang Y, Chen J, Ni C, et al. Clinical characteristics and associated factors of constipation patients with type 2 diabetes. Front Endocrinol (Lausanne).…
